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ABSTRACT
Objective: International recognition of the unique needs of young people with cancer is 
growing. Many countries have developed specialist age-appropriate cancer services 
believing them to be of value. In England, 13 specialist Principal Treatment Centres (PTC) 
deliver cancer care to young people. Despite this expansion of specialist care, systematic 
investigation of associated outcomes and costs has to date, been lacking. The aim of this 
paper is to describe recruitment and baseline characteristics of the BRIGHTLIGHT cohort, 
and the development of the bespoke measures of levels of care and disease severity, which 
will inform the evaluation of cancer services in England.
Design: Prospective, longitudinal, observational study.
Setting: Ninety-seven NHS hospitals in England.
Participants: A total of 1,114 participants were recruited diagnosed between July 2012 and 
December 2014: 55% (n=618) male, mean age was 20.1 years (SD=3.3), most (86%) were 
white and most common diagnoses were lymphoma (31%), germ cell tumour (19%) and 
leukaemia (13%). 
Results: At diagnosis, median quality of life score was significantly lower than a published 
control threshold (69.7 points); 40% had borderline-severe anxiety, and 21% had borderline-
severe depression. There was minimal variation in other patient-reported outcomes 
according to age, diagnosis or severity of illness. Survival was significantly worse in the 
Cohort than for young people diagnosed during the same period who were not recruited 
(cumulative survival probability 4 years after diagnosis: 88% vs. 92%).  
Conclusions:  Data collection was completed in March 2018. Longitudinal comparisons will 
determine outcomes and costs associated with access/exposure to PTCs. Findings will 
inform international intervention and policy initiatives to improve outcomes for young people 
with cancer.
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Strengths & limitations of this study
5 bullet points
 A cohort of teenagers and young adults with newly-diagnosed cancer was 
established with the involvement of young people in planning and operation which 
contributed to a high rate of retention.
 The socio-demographic characteristics of the cohort are broadly similar to the 
contemporary teenage and young adult cancer population, supporting the 
generalisability of results.
 Data has been collected from multiple sources including patients, individual clinical 
care records, and established National Health Service datasets.  
 The study recruited a much smaller proportion of young people diagnosed with 
cancer in the available time period, resulting in lower statistical power to address the 
impact of heterogeneity..
 A metric developed to quantify specialist care may not be sensitive enough to reflect 
the complexity of specialist care and individual patient pathways.
INTRODUCTION
BRIGHTLIGHT is a programme of research which aims to determine whether specialist care 
for teenagers and young adults (TYA) with cancer is associated with improved outcomes. 
The National Institute for Health and Care Excellence (NICE) outlined in the Improving 
Outcomes Guidance for children and young people with cancer [1] a model of specialised 
care based on a limited number of hospitals designated as principal treatment centres 
(PTC). At that time minimal information was available about either the constituent parts of 
such specialist care or the benefits that might accrue from it and why. BRIGHTLIGHT 
comprises six interlinked projects centred upon a prospective, longitudinal cohort of young 
people recruited soon after a diagnosis of cancer that examines their outcomes and 
experiences of cancer care. Additional studies address elements of specialisation; the 
environment of care [2, 3]; the competencies desirable in healthcare professionals delivering 
specialist care [4]; a metric to quantify specialist care; caregiver’s experience of care; and a 
health economic analysis to determine the cost of specialist care. The programme has been 
underpinned by an extensive patient and public involvement strategy [5-9].  
Cancer in young people is uncommon, accounting for less than 1% of all new cancer 
diagnoses in England [10]. Despite its rarity, cancer is the second leading cause of death for 
young people, accounting for 11% of deaths in those aged 15-24 years [11, 12]. In addition, 
a number of issues argue for special attention for young people with cancer and for robust 
evidence to support current and future healthcare policies. For example, young people 
present with a spectrum of cancer types that is distinct from those affecting younger children 
and older adults [11]. A cancer diagnosis during adolescence and young adulthood has an 
acute and unique impact on this critical and complex stage of life development, disrupting 
physical health, social and educational goals as well as psychological wellbeing [13]. These 
factors have additional importance when considered against the advantages which accrue to 
society from the successful treatment through the prolonged fulfilment of their contribution in 
employment and other societal impacts [14].
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While most young people are cured, outcomes for some cancers have not improved in line 
with those achieved for children and older adults [15]. There exists a general consensus 
among healthcare professionals that the needs of young people are poorly met by cancer 
services that are tailored towards the needs of children and older adults [16]. Young people 
fall between child and adult cancer services, into what has been described as either 'the 
grey zone' [17] or 'no man's land' [18]. Prolonged routes to diagnosis, unfavourable tumour 
biology with increasing age, limited access to clinical trials, lack of compliance with treatment 
protocols, inconsistent use of molecular diagnostics that may assist with optimal care, and a 
lack of specialist supportive care have all been implicated in the short fall in survival 
improvements [19-28].
Young people themselves have described unsatisfactory experiences of care which include: 
lack of recognition of their autonomy; failure to facilitate them to meet normal life goals 
during treatment; lack of peer support; care by staff with little experience of young people; 
and finally, inappropriate care environments [9, 29-31]. The inability of traditional healthcare 
silos to meet the unique psychosocial and healthcare needs of this specific population is 
increasingly highlighted [32-34]. Place of treatment and delivery of cancer care, in terms of 
both disease and age-appropriate specialist settings is increasingly acknowledged as 
potentially significant to the outcomes for young people with cancer [35, 36].
To address these unique needs and deficit in outcomes’ knowledge, in August 2005 the 
NICE Improving Outcomes Guidance recommended that all care for patients under 19 must 
be provided in age-appropriate facilities and those aged 19 and over should have 
'unhindered access to age-appropriate facilities and support when needed’ [1]. To 
accommodate this recommendation thirteen TYA PTCs were identified across England.  Key 
components of the services of the TYA PTC encompass tumour site-specific expertise 
delivered in conjunction with meeting the broader psychosocial needs of young people to 
support successful navigation of critical life transitions. This is directed through the TYA 
multi-disciplinary team (MDT) [1]. But, despite national guidance supporting this approach to 
the delivery of cancer care for young people aged 15-24 years [1]. around half of young 
people continue to be treated in children’s and adult cancer units with no or limited access to 
the TYA PTC, many receiving care in hospitals ‘designated’ by NHS commissioners to 
provide elements of specialist care that are available in a TYA PTC. 
The aim of the BRIGHTLIGHT programme of research is to evaluate the benefit of specialist 
TYA cancer services for young people aged 13–24 years. The study has four key objectives 
specific to the cohort:
1. Relate the proportion of care young people received in a TYA PTC to: quality of life, 
satisfaction with care, clinical processes and clinical outcomes
2. Examine young people’s experience of cancer care through a longitudinal 
descriptive survey
3. Compare social and educational milestones amongst young people receiving 
different levels of TYA cancer care
4. Determine the costs of specialist care to young people, their families and the NHS
 
Objectives
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The aim of this paper is to describe the complex recruitment process for establishing the 
BRIGHTLIGHT cohort, provide details of bespoke measures of levels of care and disease 
severity that were developed to inform the analysis of the evaluation, and to describe the 
baseline characteristics of the cohort.
STUDY DESIGN
The BRIGHTLIGHT cohort is a prospective longitudinal cohort study, obtaining data through 
a bespoke survey, administered through face-to-face interview, telephone interview and 
online, five times over three years: 5-7 months after diagnosis then at 12, 18, 24 and 36 
months [37].
PATIENT AND PUBLIC INVOLVEMENT
The focus of this study was identified by young people as a priority area for research. 
BRIGHTLIGHT was preceded by a period of feasibility work where we worked with young as 
co-researchers to develop the research questions, outcome measures and study design [6, 
9]. The study has a Young Advisory Panel who have worked with us since 2011, who have 
been integral in naming the study [5], study management [7, 8], identifying other areas for 
research [38] and dissemination [39].
SAMPLE AND SETTING
Participants
The BRIGHTLIGHT cohort included young people aged 13-24 years, newly diagnosed with 
cancer (ICD-10 codes C00-C97) in an English hospital and recruited within four-months of 
diagnosis. Eligibility criteria were as inclusive as possible so no restriction according to 
language or a sensory impairment that affected communication was applied. The only 
exclusion criteria were: young people receiving a custodial sentence; if the young person 
was not anticipated to be alive at the first point of data collection (6-months after diagnosis); 
recurrence of a previous cancer or they were not capable of completing a survey, e.g. 
sedated and in intensive care. 
Recruitment
Young people present with a wide range of cancer diagnoses [11]. It was anticipated that to 
identify and recruit potentially eligible patients would be the biggest challenge because of: 1) 
low incidence 2) presenting to numerous points in healthcare system, due to age and 
multiple diagnostic subtypes; and 3) inconsistent referral pathways for tertiary care. The 
NICE guidance was issued in 2005 [1], and by 2010 only 40% of newly diagnosed young 
people were known to a TYA MDT based at a PTC [40]. Analysis of the national cancer 
datasets between 2010 and 2011 indicated that young people were being treated in an 
additional 133 hospitals across England. Thus, to capture the full cohort of young people we 
needed to open recruitment in as many hospitals as possible, have a mechanism to identify 
young people across the country and also have access to an extensive network of 
researchers to recruit and administer the study questionnaires. 
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There were two mechanisms for identifying young people: first through the national Cancer 
Waiting Times (CWT) dataset, which has been reported in detail previously [41]. This is 
routinely collected NHS data used to monitor diagnostic and treatment targets; feasibility 
work suggested young people could be identified within three months of diagnosis [42]. 
However, when this method was applied nationally it was found to be neither timely nor 
accurate so a second mechanism was introduced: Principal Investigators were asked to 
liaise with the coordinators of all tumour-specific MDTs (except prostate cancer) so the 
person managing recruitment to the study could be informed of new diagnoses in young 
people aged 13-24 years. A third method to directly approach young people to invite them to 
participate was also introduced in the later stages of recruitment but did not significantly 
impact on accrual [43].
The second challenge was working with a very large number of hospitals, of which most 
were likely to identify a few eligible patients over the course of the study and who might 
present to one of several departments. BRIGHTLIGHT opened to recruitment in 109 
hospitals, of whom 97 identified and recruited between 1-106 (median 5) young people per 
hospital, 12 not recruiting any participants. England has a national network of research 
personnel funded by the National Institute for Health Research (NIHR), tasked with 
facilitating recruitment into clinical studies [41]. The aim was to recruit 2,012 young people 
diagnosed between July 2012 and December 2013. Despite making multiple targeted 
amendments to the protocol and iteratively working with NIHR researchers and the TYA 
healthcare professional community to increase the proportion of patients who were offered 
study entry (supplemental file 1), recruitment was slower and lower than anticipated. In April 
2014, an extension to recruitment until April 2015 was approved (young people diagnosed 
until December 2014, recruited within 4 months of diagnosis), and a lower target sample size 
was agreed (Figure 1). 
Ethical approval and consent
The study was approved by London Bloomsbury NHS Research Ethics Committee 
(reference LO/11/1718). Approval by the Secretary of State under Regulation 5 of the Health 
Services (Control of Patient Information) Regulation 2002 was obtained from the Health 
Research Authority Confidentiality Advisory Group (reference ECC 8-05(d)/2011) to access 
the CWT dataset, Hospital Episode Statistic (HES) data and data from the National Cancer 
Registration and Analysis Service (NCRAS).
METHODS
Data were collected from three sources: young people, patient medical records, and central 
NHS and Public Health England (PHE) databases. 
Data from young people
Patient-reported outcomes were collected from young people at five time points over three 
years: 4-7 months after diagnosis (wave 1), 12 months (wave 2), 18 months (wave 3), 2 
years (wave 4) and a final data capture 3 years after diagnosis (wave 5). Data were 
collected using a study-specific questionnaire, the BRIGHTLIGHT Survey [37] (available 
under licence from https://xip.uclb.com/i/healthcare_tools/brightlight_wave1.html), which was 
administered as a face-to-face interview in young people’s homes at wave 1. Subsequent 
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waves were administered online or through telephone interviews. At wave 1, young people 
also completed study-specific health economics questionnaires, described below.
The BRIGHTLIGHT Survey
The BRIGHTLIGHT Survey is an investigator and young person-designed self-report 
questionnaire that was administered through computer-assisted personal, telephone or web 
interviewing or web by an independent research organisation. It was developed utilising 
patient-experience literature [44] and was underpinned by a conceptual framework to guide 
question content [9]. The BRIGHTLIGHT Survey contains five validated outcome measures 
and questions to reflect young people’s experience of diagnosis and cancer care (Table 1) 
[37]. Completion of treatment occurs at different time points according to diagnosis. During 
the feasibility work young people emphasised that they did not want to be asked questions 
about cancer when treatment ended and therefore the computer administration of the 
BRIGHTLIGHT Survey had complex routing to ensure young people were only asked 
questions that were relevant to their current situation [37]. For example, questions related to 
pre-diagnosis and diagnostic experience were only asked at wave 1. The BRIGHTLIGHT 
survey also utilised ‘pull through’ options so that participants could reflect on responses 
given in previous waves before answering. For example, questions about 
employment/education goals were tailored so participants could be asked again at wave 5 to 
ascertain if goals had changed and if this was cancer-influenced.
Table 1: Summary of the content of the BRIGHTLIGHT Survey
Construct and questionnaire Details
Quality of life – Pediatric 
Quality of Life Questionnaire 
(PedsQL™) [45]
Contains 23 items scored on a 5-point Likert scale.
Four domains: physical, emotional, social and work/school 
functioning. 
Two summary scores (physical and psychosocial function) and a 
total score.
Domain, summary and total scores on 0-100 scale, with 100 
representing the best possible quality of life.
Scores <69.7 indicate a high risk of impaired quality of life [46].
Health status – Euroqol- 5 
Dimension 3 level (EQ-5D-
3L) [47]
Comprises 5 dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) scored on 3 levels (no, 
some, severe problems). 
The EQ visual analogue scale records self-reported health on a 
vertical scale ranging from ‘best imaginable health state’ to worst 
imaginable health state’.
Scores 0-1 with 0 representing death and 1 perfect health 
(negative scores represent a health state worse than death).
Anxiety and depression – 
Hospital Anxiety and 
Depression Scale (HADS) 
[48]
A measure of depression and anxiety.
Contains 14 items, scored on a four-grade scale (0 to 3). 
Summary scores for depression and anxiety (ranging from 0 to 
21). 
Scores of 8-10 are defined as borderline and 11 and over are 
considered moderate/severe anxiety and depression [49].
Social support - Multi-
dimensional Scale of 
Perceived Social Support 
(MSPSS) [50]
Scores for support by friends, family and significant others plus 
total support score. 
Contains 12 statements, rated on 7-point Likert scale. 
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Total support score is an average ranging from 1-7, sub-support 
scores range 4 – 28.
Total scale score 1-2.9 are considered low support; a score of 3-5 
is considered moderate support; and scores from 5.1-7 are 
considered high support.
Illness perception - The Brief 
Illness Perception Scale 
(BIPS) [51]
Measures the emotional and cognitive representations of illness.
Contains eight* questions with fixed response scale specific for 
each question, e.g. not at all – extremely helpful.
Each question represents a different dimension of illness 
perception: consequence, personal control, treatment control, 
timeline, identity, coherence, emotional representation, concern. 
Responses scored 1 – 10, the higher the score the greater 
perceived illness impact. 
No overall score and each question represents a single domain.
Cancer experience questions 
[37]
Comprises of 12 experience domains: pre-diagnosis experience, 
diagnostic experience, place of care, contact with healthcare 
professionals, treatment experience, fertility, involvement in clinical 
trials, adherence, communication and coordination of care, 
education, employment, wellbeing and relationships.
Total of 238 questions with question specific responses describing 
experience
*Timeline statement not included
Health economics questionnaires
Cancer/treatment related costs incurred by young people and families were collected using a 
study-specific Cost of Care Questionnaire and Cost Record. These included questions 
regarding:  travel (car parking, petrol and capital depreciation, public transport); time off 
work; medical equipment use; prescription and over the counter drug use; cost of 
accommodation incurred through hospitalisation; complementary and alternative medicine; 
and cost of family care for siblings. The Cost of Care Questionnaire was administered at 
wave 1 and required young people and their families to record costs incurred from the above 
items retrospectively since diagnosis. The Cost Record was given at waves 1 and 2, 
requesting the same information collected prospectively, on a weekly basis.
Data from medical records
Research teams who recruited young people completed an electronic Case Report Form 
(CRF) 12 months after diagnosis, which contained key variables relating to diagnosis, 
treatment, clinical process and outcome variables. This included postcode at the time of 
diagnosis, locations of care, details of diagnosis, MDT treatment planning and care, and 
outcomes at 12 months after diagnosis. The Index of Multiple Deprivation (IMD) is a 
measure of socioeconomic status [52] and was derived from the postcode at diagnosis, 
based on the population denominator of England. Clinical processes of care were defined as 
documentation of:
1. Histological diagnosis 
2. Molecular diagnosis 
3. Cancer stage or prognostic group
4. Initial treatment plan 
5. Evidence of multidisciplinary communication 
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6. Assessment by supportive care services, defined as documented contact with a 
Clinical Nurse Specialist plus one other member of the MDT (social worker, youth 
support coordinator, counsellor, psychologist, dietician, physiotherapist, occupational 
therapist) 
7. Fertility discussion 
8. Consideration for inclusion in a clinical trial  
Data from national datasets
Data from NCRAS and HES were used to supplement and validate details of treatment 
received in the TYA PTC, to support a detailed health economic evaluation based on 
hospital attendance and healthcare received, and to cross check against the e-CRF. NCRAS 
data included date of diagnosis, tumour morphology, staging and treatment data; and HES 
data included dates for admitted patient care (APC), outpatient and accident and emergency 
attendance, plus receipt of chemotherapy and radiotherapy. 
DEVELOPMENT OF BESPOKE METRICS
Defining levels of care
BRIGHTLIGHT aims to evaluate exposure to specialist TYA cancer services, defined as 
treatment in the TYA PTC. In recognition that patients may receive elements of care in more 
than one hospital, we proposed that care could be categorised by three levels according to 
the proportion of care received in a TYA PTC. To accurately allocate cohort participants to 
the appropriate level of care, analysis of HES data were used. In summary, PTC Trust codes 
were identified for 2012-2014 and applied to HES data so the proportion of days spent in a 
TYA PTC in the first 6 months and 12 months after diagnosis could be calculated (details 
provided in supplemental file 2). 
Defining severity of illness
Advanced cancer is associated with poorer quality of life [53, 54]. We planned to compare 
quality of life of those treated in different care environments. To do so, we needed to 
consider ways to control for differences between patients which might influence this outcome 
and in particular, the severity of their cancer.  However, this is difficult for TYA as they 
present with a heterogeneous array of malignancies [11]. While most cancers have staging 
criteria which differentiate between more or less extensive disease (typically groups 1-4 in 
ascending order of worsening survival), stage is not directly comparable between cancer 
types and a comparison based purely on staging would be meaningless due to the variation 
in outcomes between different cancers allocated to the same stage level. For example, 
stage 4 thyroid cancer is associated with a much higher chance of survival than say, stage 4 
bowel cancer. Furthermore, survival alone is a good indicator of severity of illness as it takes 
no account of disease and treatment morbidity both for the short and long term.  We 
therefore developed a bespoke ‘severity’ grading system to include symptom and treatment 
burden as well as predicted survival and burden of late effects. Each cancer type was 
graded as least, intermediate and most severe based on cancer-specific information thus 
allowing comparisons between groups of patients with multiple types of cancer (Table 2; 
detailed methodology is presented in supplemental file 3).
ANALYSIS
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The number of young people at each stage of the project were described using a flow 
diagram, including the numbers eligible, consenting to be involved, and followed up at each 
survey point. Reasons for non-participation at each stage were summarised. Potentially 
eligible patients who did not participate in the cohort study were compared against those 
who consented with regard to age, gender, ethnicity, location (based on the network linked 
to each PTC) and diagnosis. Data in both groups were summarised as means with standard 
deviations (sd), medians with interquartile ranges (IQR) or frequency and percentage (%), as 
appropriate and comparisons made using standard Chi squared and t-tests Since sample 
sizes for these comparisons were very large, statistical significance is defined as P<0.001. 
 Survival from diagnosis was summarised using Kaplan Meier plots and the cohort and non-
cohort groups compared using Cox regression to adjust for age, gender, ethnicity, location 
and type of cancer. Patient reported outcomes collected in the first wave were scored 
according to published guidance for each of the validated measures. The characteristics of 
the cohort were summarised using means/medians (sd/IQR) or frequency (%) as 
appropriate. 
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Table 2: BRIGHTLIGHT Severity of Illness Index (see supplemental file 3)
Cancer type [11] Least severe Intermediate severity Most severe
Germ cell tumours Stages 1-3; Stage unknown Stage 4 (stage 1S=stage 4)
Leukaemias CML ALL; Other and unspecified AML
Non-Hodgkin lymphoma 
and non-specified 
lymphoma
Over 16yrs, protocol unknown 
Stage 1-2
Over 16s, protocol unknown; Stage 3-
4; Any paediatric-type protocol; All 
unknown
Burkitts (ICD10 C83.7, morphology code 9687/3)
Hodgkin lymphoma All stages
Central nervous system 
tumours
Pituitary adenomas (D35.2);  Sub-
ependymal giant cell astrocytoma 
(C43.2)
Other completely resected WHO 
grade I tumours for which surgery is 
the only treatment needed - except 
craniopharyngiomas
Craniopharyngiomas; incompletely resected or 
unresectable grade I tumours; all grade II-IV 
tumours, any needing radiotherapy or 
chemotherapy. This includes ependymomas, 
medulloblastomas and intracranial GCTs
Bone tumours Surgery only (low grade, 
periosteal, parosteal)
All other
Soft tissue sarcoma Stages 1-2 Stage 3; Unknown Stage 4
Rhabdomyosarcoma Low risk EpSSG A-D1 All others; Unknown
Melanoma Stages 1-2 (except 2c)
Stage 2c; Stage 3 (except 3c); Stage 
unknown
Stage 3c; Stage 4
Carcinoma
All thyroid; All Stage 1; Cervix 
stage unknown
Stages 2-3; All nasopharyngeal; 
Stage unknown (except cervix)
Stage 4
Miscellaneous and 
unspecified
All
1 EpSSG: European Paediatric Soft Tissue Sarcoma Study Group
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RESULTS
A total of 1,126 young people were recruited for whom valid consent was available from 
1,114 (Figure 2). Recruiting hospitals were required to keep a screening log, which was 
returned to the BRIGHTLIGHT team by 95 (87%) hospitals when recruitment ended. Of the 
2,900 young people who had been screened, 429 (15%) were reported as not being eligible 
and 1,877 (65%) were eligible to participate. No details were provided for the remaining 594 
(20%). Only 426 (23%) of those eligible had refused to participate, which was lower than the 
35% we had anticipated and accounted for [8]. Of the 15% recorded as being ineligible, just 
over half (225, 52%) had either no reason recorded or appeared to have been deemed to be 
ineligible incorrectly. 
Data were obtained from NCRAS for young people diagnosed in the same time period, who 
were potentially eligible, i.e., alive 6-months after diagnosis and place of residence was not 
linked to a prison postcode. A total of 5,953 young people were diagnosed with cancer 
between July 2012 and December 2014, of whom 5,835 (98%) were potentially eligible to 
participate1; 1,114 (19%) appeared in the BRIGHTLIGHT Cohort. 
Clinical and NHS data were available for all 1,114 young people. Of these, 830 (75%) 
completed the wave 1 survey (Figure 2). In total, 163 (20%) participated once, 186 (22%) 
twice, 195 (24%) completed three, 173 (21%) completed four and 113 (14%) took part in 
every wave.
Non-participants were similar in age and ethnicity to those in the BRIGHTLIGHT cohort but 
there were differences in gender (a lower proportion of males in non-participants) and 
inclusion by tumour type (a greater proportion of young people with leukaemia and 
lymphoma, germ cell tumours and bone tumours compared to non-participants but lower 
representation of brain tumours, skin cancers and carcinomas) (Table 3).
Table 3: Comparison of characteristics of participants and non-participants
N BRIGHTLIGHT 
Cohort
N Non-
Participants
P-
values3 
Age at Diagnosis 
(years)
Mean (SD)
Median (IQR)
1114 20.13 (3.28)
20.64 (17.58, 22.95)
4721 19.94 (3.33)
21 (17, 23)
0.08
Gender Male
Female
1114 618 (55%)
496 (45%)
4721 2213 (47%)
2508 (53%)
<0.0001
Ethnicity White
Asian
Black
Chinese
Mixed
Other
1085 936 (86%)
82 (8%)
22 (2%)
4 (<1%)
26 (2%)
15 (1%)
4316 3643 (84%)
288 (7%)
156 (4%)
34 (<1%)
74 (2%)
121 (3%)
0.002
Type of cancer1 Leukaemia
Lymphoma
CNS
1114 145 (13%)
350 (31%)
46 (4%)
4721 300 (6%)
781 (17%)
735 (16%)
<0.0001
1 109 young people died within 6-months of diagnosis so were assumed to be too sick to be 
approached and nine were in prison.
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Bone
Sarcomas
Germ cell 
Skin
Carcinoma (not skin)
Miscellaneous specified
Unspecified malignant
102 (9%)
78 (7%)
212 (19%)
45 (4%)
125 (11%)
9 (<1%)
2 (<1%)
177 (4%)
207 (4%)
504 (11%)
709 (15%)
1210 (26%)
55 (1%)
43 (1%)
Geographical 
location2
Birmingham
Bristol
Cambridge
Manchester
Merseyside
East Midlands
Leeds
Newcastle
Oxford
London (south)
Sheffield
Southampton
London (north)
1114 155 (14%)
116 (10%)
23 (2%)
103 (9%)
42 (4%)
135 (12%)
106 (10%)
59 (5%)
19 (2%)
77 (7%)
37 (3%)
83 (8%)
159 (14%)
4618 459 (10%)
351 (8%)
276 (6%)
391 (8%)
239 (5%)
278 (6%)
254 (6%)
305 (7%)
249 (5%)
668 (14%)
174 (4%)
221 (5%)
753 (16%)
<0.0001
CNS: central nervous system; SD: standard deviation; IQR: interquartile range
1 Based on the Birch classification [11]
2 Hospitals mapped to the multidisciplinary team at the Teenage and Young Adult Principal Treatment Centre 
they were linked to
3 P-values from Chi squared tests and t-tests as appropriate. 
Of the 1,114 young people in the BRIGHTLIGHT cohort, 618 (55%) were male, mean age at 
diagnosis was 20.13 years (SD 3.28) and 936 (86%) identified themselves as white. 
Lymphoma was the most common cancer type (n=350; 31%), followed by germ cell tumours 
(n=212; 19%) and leukaemia (n=145; 13%) (Table 3). Table 4 details the sociodemographic 
and clinical characteristics of the BRIGHTLIGHT cohort. There was an even distribution 
across socioeconomic groups. Most were single (n=606; 84%) and employed or in education 
(n=531; 64%). Systemic anti-cancer therapy was the most common form of treatment, used 
for 880 (79%). Thirty (3%) young people received no treatment, just active monitoring. The 
clinical processes that were most frequently documented in the clinical records were MDT 
communication (n=1037; 97%), cancer stage or prognostic group (n=1015; 94%), histology 
(n=974; 91%) and initial treatment plan (n=974; 91%). One hundred and sixty seven (20%) 
young people reported having a pre-diagnosis long-term condition.
Table 4: Socio demographic and clinical characteristics of the BRIGHTLIGHT Cohort 
Characteristic Number %
1 – most deprived 250 23Socioeconomic status 
(IMD quintile) 2 194 18
(N=1088) 3 209 19
4 230 21
5 – least deprived 205 19
Marital Status Married/civil partnership 26 4
(wave 1; N=725) Cohabiting 93 13
Single/divorced 606 84
Current status Working full/part time 257 31
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(at wave 1; N=830) In education 274 33
Other work (apprentice/intern/voluntary) 17 2
Unemployed 31 4
Long term sick 126 15
Not seeking work 125 15
Length of inpatient 
stay over 12 months 
(N=1070) days
Median (IQR) 25 9 to 74
Treatment (N=1114)2 Systemic anti-cancer therapy 880 79
Radiotherapy 324 29
Surgery 551 50
Active monitoring 30 3
Transplant (stem cell or bone marrow) 28 3
Severity of illness Least 611 55
(N=1114) Intermediate 254 23
Most 249 22
Histological diagnosis (n=1072) 974 91
Molecular diagnosis (n=737)3 258 35
Cancer stage or prognostic group (n=1078) 1015 94
Clinical processes of 
Care (documentation
available in clinical 
records) Initial treatment plan (n=1071) 974 91
MDT communication (n=1074) 1037 97
Assessment by supportive care services (n=1057) 563 53
Fertility being discussed (n=1063) 693 65
Consideration into a clinical trial (n=1057) 676 64
CNS: central nervous system; IMD: Index of Multiple deprivation; IQR: interquartile range
1Based on period of 12 months from diagnosis. Missing for 70 participants: 26 had no days in hospital after 
diagnosis (inpatient stay was before diagnosis date) and data were missing for 44 
2 N greater than 1114 reflects multiple treatment modalities for some diagnoses
3 Where relevant, indicated as not relevant in 320                                                   
A total of 124 (11%) young people in the BRIGHTLIGHT cohort died before 31st December 
2016. Results from Cox regression indicate that a survival benefit for non-BRIGHTLIGHT 
patients was maintained even after adjustment for age, gender, ethnicity and type of cancer; 
the risk of death was 34% higher for those in the BRIGHTLIGHT cohort compared with those 
not in the cohort. (Figure 3; hazard ratio estimate 1.34 (95% confidence intervals 1.09-1.68), 
p=0.01; table 5). There was no evidence that survival of cohort participants compared with 
non-participants differed by cancer type (P-value for interaction P=0.12). 
Table 5: Comparison of survival between participants in the Cohort and non-participants1
Estimated cumulative survival probabilities by year from diagnosis  (95% 
CI)
Non-participants BRIGHTLIGHT cohort
1 year 0.98  (0.97, 0.98) 0.98 (0.97, 0.99)
2 years 0.95 (0.94, 0.96) 0.92 (0.91, 0.94)
3 years 0.93 (0.92, 0.94) 0.89 (0.87, 0.91)
4 years 0.92 (0.91, 0.93) 0.88 (0.85, 0.90)
CI: confidence intervals
Log rank test P value <0.0001 
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1Non-participants were young people diagnosed in the same time frame as the 
BRIGHTLIGHT cohort identified by the National Cancer Registration and Analysis Service 
(NCRAS), who were not part of BRIGHTLIGHT
A summary of patient-reported outcomes recorded at wave 1 are presented in Table 6. 
Mean total quality of life, physical and emotional domain scores were <69.7 indicating that, 
on average, young people had some impairment to quality of life shortly after diagnosis [46]. 
This is particularly notable in terms of physical scores where the average was significantly 
below the threshold, by more than 10 points, for a clinically important difference [55, 56]. 
Forty percent of young people could be classified as ‘cases’ for anxiety and 22% for 
depression (borderline-severe) [49]. Young people reported high levels of support from 
friends (Multi-dimensional Scale of Perceived Social Support cut off >5) and moderate 
support from family and significant others (score 3-5) [50]. The Brief Illness Perception Scale 
results indicate that young people felt cancer had a moderate effect on their life but they 
perceived that treatment was extremely helpful. They perceived themselves as having 
experienced a moderate number of symptoms and believed they had a good understanding 
of their cancer. The majority rated their satisfaction with care as being excellent/good 
(n=777; 94%). Those aged 19-24 years seemed to have better physical and psychosocial 
quality of life compared to those aged 13-18 years at diagnosis. This older age group also 
reported more anxiety, lower social support, better perceived personal control but lower 
perceived emotional representation and concerns. According to diagnosis, young people 
with a solid tumour had better physical scores, perceptions of consequences and identity but 
less support from friends than those with a blood cancer. Finally, there was a noticeable 
trend for better total quality of life, physical and psychosocial scores for those with less 
severe disease and worse emotional score for the intermediate severity group. Young 
people with less severe disease had better perceived consequences and identify but 
satisfaction with care was highest in those with the most severe disease. 
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Table 6: Summary of the wave 1 patient-reported outcomes 
Age Diagnosis Severity of illness
Characteristic N All patients
N=830
13-18yrs
N=302
19-24yrs
N=528
Haematology
N=373
Oncology 
N=457
Least
N=461
Intermediate
N=194
Most
N=175
PedsQL - mean (SD)
Total score 829 66.20 (19.79) 64.14 (18.53) 67.39 (20.40) 64.59 (18.28) 67.52 (20.86) 70.67 (18.86) 61.55 (19.77) 59.57 (19.25)
Physical summary score 828 59.45 (27.72) 54.67 (26.75) 62.20 (27.91) 56.96 (25.04) 61.47 (29.58) 67.65 (25.49) 52.67 (26.63) 45.33 (26.95)
Psychosocial summary score 80.38 (18.45) 77.88 (18.27) 81.82 (18.42) 79.37 (18.49) 81.21 (18.41) 84.15 (16.75) 75.90 (19.82) 75.43 (18.98)
Emotional summary score 67.64 (22.76) 70.94 (21.83) 65.75 (23.07) 67.75 (21.68) 67.55 (23.62) 68.05 (23.09) 64.92 (23.15) 69.57 (21.21)
EQ-5D – mean (SD) 
Total score
830 0.76 (0.24) 0.75 (0.23) 0.77 (0.24) 0.77 (0.22) 0.76 (0.25) 0.81 (0.21) 0.71 (0.26) 0.71 (0.24)
- median (IQR) 0.80 (0.69-1) 0.80 (0.62-1) 0.81 (0.69-1) 0.80 (0.69-1) 0.80 (0.66-1) 0.85 (0.73-1) 0.73 (0.62-1) 0.75 (0.59-0.88)
HADS – mean (SD)1 830
Anxiety score 6.89 (4.39) 6.14 (4.12) 7.32 (4.49) 6.79 (4.36) 6.98 (4.43) 7.23 (4.55) 7.01 (4.44) 6.14 (3.83)
- Borderline n (%) 160 (19%) 51 (17%) 109 (21%) 75 (20%) 85 (19%) 82 (18%) 44 (23%) 34 (19%)
- Moderate/severe n (%) 172 (21%) 48 (16%) 124 (23%) 70 (19%) 102 (22%) 106 (23%) 40 (21%) 26 (15%)
Depression score 4.62 (3.68) 4.45 (3.38) 4.71 (3.84) 4.84 (3.57) 4.43 (3.76) 4.31 (3.65) 5.16 (3.79) 4.81 (3.57)
- Borderline n (%) 120 (15%) 40 (13%) 80 (15%) 48 (13%) 72 (16%) 48 (10%) 40 (21%) 32 (18%)
- Moderate/severe n (%) 55 (7%) 16 (5%) 39 (7%) 26 (7%) 29 (6%) 32 (7%) 14 (7%) 9 (5%)
MSPSS – median (IQR)
Total support 820 1.50 (1.08-
2.25) 
1.58 (1.17-
2.33)
1.50 (1-2.08) 1.58 (1.08-2.25) 1.42 (1.08-
2.17)
1.50 (1.08-
2.25)
1.58 (1-2.25) 1.50 (1.17-2.08)
Support - friends 827 7 (4-11) 7 (4-12) 6 (4-10) 7 (4-11) 6 (4-10) 7 (4-10) 7 (4-12) 7 (4-10)
Support - family 827 5 (4-8) 5 (4-8) 5 (4-8) 5 (4-8) 5 (4-8) 5 (4-8) 5 (4-8) 4 (4-7)
Support – significant others 823 4 (4-8) 5 (4-9) 4 (4-8) 4 (4-8) 4 (4-8) 4 (4-8) 4 (4-9) 4 (4-7)
BIPS – median (IQR) 830
Consequences 7 (4-8) 7 (5-8) 7 (4-8) 7 (5-8) 6 (4-8) 6 (4-8) 7 (5-8) 7 (6-9)
Personal control 6 (4-8) 6 (5-8) 5 (3-8) 6 (4-8) 6 (4-8) 6 (3-8) 6 (4-8) 6 (3-8)
Treatment control 10 (9-10) 10 (9-10) 10 (8-10) 10 (9-10) 10 (8-10) 10 (9-10) 10 (9-10) 10 (8-10)
Identity 5 (3-7) 6 (3-8) 5 (3-7) 6 (4-7) 5 (2-7) 5 (3-7) 6 (3-8) 6 (4-8)
Coherence 8 (7-10) 9 (7-0) 8 (7-10) 8 (7-10) 8 (7-10) 8 (7-10) 8 (7-10) 9 (7-10)
Emotional representation 6 (4-8) 5 (3-7) 7 (4-8) 6 (4-8) 6 (4-8) 6 (4-8) 6 (4-8) 6 (3-8)
Concern 6 (3-8) 5 (3-7) 7 (4-8) 6 (3-8) 6 (4-8) 6 (3-8) 6 (4-8) 6 (3-8)
Satisfaction with care – n 
(%)
820
Excellent/good 777 (95%) 284 (95%) 493 (95%) 358 (96%) 419 (94%) 433 (95%) 173 (91%) 171 (99%)
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Fair/poor/very poor 43 (5%) 16 (5%) 27 (5%) 15 (4%) 28 (6%) 23 (5%) 18 (9%) 2 (1%)
BIPS: Brief Illness Perception Scale; EQ-5D: Euroqol 5-Dimension; HADS: Hospital Anxiety and Depression Scale; IRQ: interquartile range; MSPSS: Multi-dimensional Scale 
of Perceived Social Support; PedsQL: Pediatric Quality of Life Questionnaire;SD: standard deviation
1Borderline = 8-10, moderate/severe = >11 [49]
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DISCUSSION
The BRIGHTLIGHT cohort is the first national, prospectively recruited cohort of teenagers 
and young adults with cancer. We are able to examine in detail the complexity associated 
with place of care, experience and outcome. This is made possible through the use of linked 
data from multiple sources so unlike other cohorts which rely solely on patient-reported 
outcomes [34, 54] or clinical data [32], a more comprehensive evaluation can be derived. 
Using national mandatory NHS datasets we have been able to calculate a more robust 
measure of time spent in specialist TYA care. Other data sources, such as secondary 
analysis of the National Cancer Patient Experience data is based on TYA PTC code at the 
time of participation [57], as such this reflects a single point in time and does not reflect 
experiences and outcomes for those who have exposure to both specialist and non-
specialist care. Measuring exposure to a TYA PTC through analysis of HES data has 
enabled a more objective exposure variable to be developed. Similarly, defining severity of 
cancer through prognosis for survival alone does not reflect the symptom/treatment burden 
of disease and the impact this has on quality of life during treatment and recovery. 
Systematically defining prognosis alongside symptom and treatment burden, provides a 
more nuanced measure and is a better reflection of the severity of illness.
Selecting the study design to evaluate TYA cancer services across England was challenging 
as services were already in place and, in some regions of the country, long-established. 
There was also wide variation in implementing the NICE Guidance [1] according to local 
need and pre-existing resources, resulting in services at PTCs not being identical. The 
decision to establish a cohort was made on the basis that it is suited for investigating rare 
exposures, allows examination of multiple outcomes for the defined exposure (to specialist 
care), and would enable us to gather data regarding sequence of events, with the potential 
to assess causality. The main limitation of the cohort is we only recruited a fifth of the 
population who were eligible to participate. Variation in diagnosis and severity between 
those in the cohort receiving different level of PTC care reduces the potential to assess 
causality. 
Cohort studies are acknowledged to be challenging to establish and maintain, especially in 
rare conditions due to the requirement for large numbers of subjects, potential for selection 
bias and the challenges associated with subject retention [58-61]. We anticipated that 
participation might favour those who were less unwell or had a better prognosis. The 
inclusion of significant numbers with tumours associated with poorer prognosis such as bone 
tumours and the inferior survival of the cohort go against this. One of the aims of the 
BRIGHTLIGHT was to evaluate socioeconomic variation in access to specialist care. A 
comparison of IMD quintile between those who were and were not recruited who have 
enabled us to assess whether there was bias in recruitment according to difference 
socioeconomic groups; however, these data were not available but warrant exploration in the 
future. Our experience of recruitment points to the value of maintaining accurate screening 
logs and seeking mechanisms to complement the intelligence from local teams about 
change of status of participants such as death or change of address.  
Our experience highlights the value of patient and public participation in research. We have 
described earlier in the paper the involvement young people had from study inception to 
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dissemination. In total more than 1,200 young people have been involved in BRIGHTLIGHT 
as part of the research process almost the same number as those recruited. We believe this 
has positively influenced the rates of participation, ways in which young people were 
approached and methods of data collection, and doubled the retention rate at Wave 3 [7].
This population is known to have lower involvement in clinical trials in comparison to children 
and older adults [22, 62], yet there have been no targeted interventions developed to 
improve recruitment [63]. We have reported that to optimise recruitment to clinical trials, 
what we have identified as ‘the 5’A’s’ need to be addressed, namely availability, 
accessibility, awareness, appropriateness, and acceptability [62]. We have identified factors 
that young people feel are acceptable for accessing research [8] and for continuing their 
involvement in a study [7]. We have also identified that the networked structures for 
facilitating recruitment into cancer research in England may not be optimal for the 
recruitment of young people [41]. The impact of not having an optimal research network was 
made apparent through BRIGHTLIGHT, as it was the first national study in this population. 
Ways to overcome this challenge are currently being explored by the NIHR.
A potential limitation of the BRIGHTLIGHT cohort study is the outcome measures that were 
selected to be included in the survey. Traditionally outcome measures are developed for 
children less than 18 years or adults older than 18. Our population crossed both age groups 
so there were limited measures validated for use in this population. Our measure of quality 
of life, the PedsQL, has been validated for use in adolescence and adulthood [45] and has 
been used often in TYA cancer studies [34, 64-67]. The other measures, outlined in Table 1, 
had no formal psychometric testing specifically in a TYA cancer population. However, these 
have been used extensively in studies in young people with and without cancer [68-74] so 
we are confident the results reflect a consistent measure of each construct, but warrants 
further exploration of the data in the future.
FUTURE PLANS
The BRIGHTLIGHT cohort was originally designed to evaluate short-term outcomes, from 
early after diagnosis to three years after diagnosis, over five time points. Data collection for 
wave 5 ended in February 2018, with results for the four key objectives anticipated to be 
available by the end of 2018. As noted earlier, the study has generated a large quantity of 
data and with the recent completion of a James Lind Alliance Priority Setting Partnership 
exercise for TYA exercise (http://www.ncri.org.uk/ncri-blog/top-10-research-priorities-for-
teenage-and-young-adult-cancer-identified/), there is the opportunity to address some of the 
unanswered questions with the BRIGHTLIGHT cohort. This opportunity has already been 
realised to contribute evidence to improvements in early diagnosis [19]. In line with NIHR 
guidance, patient-reported outcome data from the cohort will be made available to external 
researchers on acceptance of the final report in the NIHR Journal Library. Details of how to 
apply will be made available on the website (www.brightlightstudy.com). 
The philosophy of specialist TYA cancer care is to provide optimal cancer treatment 
alongside the developmentally-sensitive care that enables young people to achieve their life 
goals (e.g. education, employment, relationships) during treatment and beyond. 
BRIGHTLIGHT will evaluate this in the short-term but longer-term follow-up may be valuable 
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to explore whether the model of care delivery influences these outcomes later in life. We are 
now planning a 10-year follow-up study to assess the long-term impacts. We also 
acknowledge that similar to other studies quantifying care using NHS data [57, 75], the 
measure of specialist care may lack discrimination, not least because it assumes that all 
TYA PTCs and other places of care are equal. Additional to the cohort, a case study was 
conducted to understand the culture of TYA cancer care [3]. There is the potential to 
synthesise the qualitative findings from the case study with the quantitative data from the 
cohort to develop a more detailed and sensitive metric to define specialist TYA cancer care. 
Ultimately, the data generated by the cohort and BRIGHTLIGHT will provide new information 
on cancer in young people and determine if access to a PTC adds value. The relationships 
between specialist care and outcomes have previously been unclear. Findings will inform 
intervention and policy efforts to improve outcomes for young people with cancer.
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Figure 1: Summary of actions undertaken to improve recruitment and impact on accrual 
figures
i. Open to most Trusts agreeing to participate (n=77); posters to advertise BRIGHTLIGHT 
distributed to all Trusts
ii. Information to all newly diagnosed young people distributed in CLIC Sargent information 
packs; top recruiters reported in the TYAC weekly bulletin (the professional organisation in 
the UK supporting healthcare professionals with adolescents and young adults with cancer)
iii. Healthcare professional information leaflets sent  to all Trusts (hard copy and electronic for 
local distribution)
iv. Director/Assistant Directors of the National Cancer Research Network emailed all the Cancer 
Network Managers directing them to make recruitment to BRIGHTLIGHT a priority; approved 
amendment to allow consent to be taken the same time a giving the information sheet
v. Review of screening logs and site specific feedback presentations sent to each Principal 
Treatment Centre (PTC)
vi. Open to recruitment in all 13 PTCs
vii. Approval to use social media to recruit young people; open in all 109 Trusts agreeing to open 
to recruitment
viii. Attendance at a Teenage Cancer Trust Lead Nurse event to highlight recruitment issues and 
gain support
ix. Emails sent by universities (communication teams or student unions) to current students with 
a link to the website to capture young people continuing with education after diagnosis; 
training for Youth Support Coordinators to be able to recruit young people
x. Attend a CLIC Sargent Social Worker event to promote the study and gain support to take a 
recruitment role
xi. Information on the BRIGHTLIGHT website in video format
xii. Recruitment method based on the National Cancer Patient Experience Survey implemented
Figure 2: A summary of participation at each wave of data collection
* Drop outs between waves due to death, permanent opt-out or wave opt out. Wave opt-outs prior to being issued 
were not permanent opt-outs; participants could opt-out of a single wave but participate in subsequent waves; 
these cases were not removed from the cohort permanently
Figure 3: Comparison of survival between participants in the Cohort and non-
participants1
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Supplementary File 1 Detailed results of actions implemented to improve recruitment to the cohort 
 
Table A: Possible challenges reported by healthcare professionals before recruitment began and strategies identified to overcome them 
 Challenges Strategies proposed to overcome challenges  
Identifying young people Missing eligible young people if transferred to regional 
specialist centres 
Recruiting across a range of hospital sites 
Recruiting across multiple tumour types 
Engaging consultants: one concern was they would not 
think the older TYAs were eligible,  a perception being 
that it was a ‘teenager’ study 
Use the TYA MDT meetings to identify  young people  
Co-ordination by a key person such as the Lead Nurse, cancer 
network head, or MDT lead to ensure details of eligible TYAs 
are passed to the recruiters 
Collaborative working with other centres to ensure all young 
people are approached, but not on multiple times  
Approaching/consenting 
young people 
Concerns about ‘getting past’ protective and upset 
parents 
Timing of consent, particularly if the patient is undergoing 
chemotherapy and was likely to be feeling very unwell  
Lack of experience in working with ‘children’ 
Being seen or felt to ‘pressurise’ potentially ‘vulnerable 
and fragile’ young people to take part 
Getting treating consultant approval to approach young 
people 
Encouraging the  initial approach to be a conversation, and not 
be immediately about persuading young people to take part 
Work with paediatric nurses to help with recruiting younger TYA 
Undertake paediatric consent training 
Wait for a sufficient length of time after diagnosis – maybe two 
months – before introducing the study, to allow the young 
person to become accustomed to the emotional and practical 
impact of the diagnosis  
TYA: Teenage and young adult; MDT: multi-disciplinary team 
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Table B: Suggestions from healthcare professionals for keeping young people engaged throughout the study 
Suggestion to keep young people engaged Action for implementation by BRIGHTLIGHT 
Get the consent process absolutely right: clear, accurate information about 
the survey, as buy-in from young people will increase the chances they will 
continue to participate 
Information developed with young people, site initiation with recruiters to 
ensure they knew about the study and could relay information to young 
people in the best way 
Provide TYA-friendly formats: e.g., ensure the survey could be completed 
on an iPad or iPhone as well as on a home computer 
The survey was administered face-to-face at the first time point; 
subsequently it could be completed online on any platform 
Use the internet: communicate via social networks like Facebook and 
Twitter 
An open Facebook account was prohibited by the sponsor Trust but a 
Twitter account was opened 
Ensure language used is aimed at empowering young people All information was reviewed by the YAP1 and had a reading ease of >70% 
Consider incentives: e.g., a medal-based reward system – for each year 
young people remain in the study they move up the medals from Bronze 
(Year 1) to Silver (Year 2) and Gold (Year 3) and get a correspondingly 
increasingly valuable reward each time. 
The YAP suggested a reward system using wrist bands with a different 
colour for each wave of participation 
Inform participating young people on why the study matters and why their 
continuing involvement is important 
A website was developed to keep young people updated about the 
programme www.brightlightstudy.com 
Maintain contact throughout Newsletters 
Disseminate progress and results so they can see the wider scale and 
impact of the survey, that is making a difference 
Content of  newsletters related to results as far as was possible 
Keep parents on board perhaps with targeted communications Newsletters sent to all the email addresses provided  
Distribute posters and flyers to treatment centres Posters and flyers provided 
YAP: Young Advisory Panel; TYA: teenage and young adult 
1YAP are the BRIGHTLIGHT patient user group 
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Table C:  Suggestions for how the BRIGHTLIGHT Team might facilitate recruitment and actions taken to address these 
Suggested change Action by the BRIGHTLIGHT Team 
1. Study information for health 
professionals 
 
An information booklet was developed giving a brief summary of the study. This was sent electronically 
and as hard copies to all participating Trusts. 
 
Regular newsletters were developed and circulated online and as hard copies.  
 
Recruitment figures were circulated in a weekly Bulletin by TYAC to their members and were also 
Tweeted by the BRIGHTLIGHT team (@bR1GhTLiGhT)  
2. Make the participant information sheets 
as short as possible 
 
A summary booklet had been produced by Ipsos MORI1 to send as a reminder about the study by their 
interviewers. An ethics amendment was made in July 2013 to allow this to be used in conjunction with 
the lengthy information sheet at the time of consent. 
 
Video versions of the information sheet were made available on the website (www. 
http://www.brightlightstudy.com/user-involvement/) 
3. Investigate any variation in recruitment 
rates between sites 
 
Screening logs were r quested and analysed to identify reasons for suboptimal recruitment, which was 
fed back to each Trust with guidance on how to overcome recruitment issues. 
4. Reduced interval between giving 
information and getting consent2 
An amendment was approved by the Ethics Committee to allow consent to be taken within the same 
24-hour period as information was given. 
5. Provide BRIGHTLIGHT advertising 
materials  
 
Posters, flyers and postcards had been available since the beginning of the study. These were 
distributed not only by the BRIGHTLIGHT Team but also by CLIC Sargent and Teenage Cancer Trust. 
6. Keep sending the NWCIS notification3 
 
There was a temporary pause in the CWT data being sent due to organisational change of NWCIS to 
Public Health England.  
7. Extend the window of recruitment for 
wave 1   
 
This was relaxed at the end of 2012 so young people could be recruited at any time in the first four 
months after diagnosis. We were unable to extend recruitment beyond this period because we wanted 
data to be collected within a specific time window. Young people were not able to enter the study at 
later time points because subsequent questions were informed by responses in the first survey. 
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Table C. cont.  
 
Suggested change Action by the BRIGHTLIGHT Team 
8. Reduce the number of times young 
people need to participate (total study 
participation involved 5 time points in 3 
years) 
 
The sample size calculation was based on participation at three time points (as specified in the 
protocol) because we were aware young people might opt in and out of participation depending on their 
current life commitments. We developed top tips for recruiting Trusts, including information about 
participation. The top tips were prominent on the website, were sent as an information leaflet, and 
included in the newsletter. 
9. Enable information sheets to be posted 
to young people 
 
An ethics amendment was approved to enable information sheets and consent forms to be posted 
and/or returned through the mail.  
10. Make presentations at local network and 
Trust meetings 
 
Members of the BRIGHTLIGHT team presented recruitment updates at every available national 
meeting. Trusts were also informed that the team would come to any local meetings on request. Site 
specific slides to present at MDTs were provided to all PTCs.  
11. First survey to be online or telephone 
rather than face-2-face 
 
This request could not be accommodated. A single mode of administration had been developed for the 
first survey.4 
CWT: Cancer Wait Time database; MDT: multi-disciplinary team; NWCIS: North West Cancer Intelligence Service (after the move to Public Health England became known as 
the North West Knowledge Intelligence Team). PTC: Principal Treatment Centre; TYAC: Teenagers and Young Adults with Cancer (the organisation representing healthcare 
professionals working in this area). 
1 Ipsos MORI were the commercial company administering the BRIGHTLIGHT Survey; 2 Ethics guidance in the United Kingdom recommends a minimum of 24 hour between 
providing information and gaining consent to give participants time to process information; 3 NWCIS sent a monthly email to a dedicated person in each recruiting trust with a 
list of potentially eligible patients identified through the Cancer Waits dataset as newly starting treatment; 4Subsequent waves had a choice of online or telephone interviewer 
administered survey; the online option has only been selected by a minority of young people 
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Supplemental file 2: Method for calculating the TYA Cancer Specialism Scale (TYA 
CSS) to assign level of care 
 
The TYA CSS is derived from admitted patient care data using linked Hospital Episode 
Statistic (HES) data. HES data from 2011/12 to 2016/17 were obtained from NHS Digital and 
linked to patients from the BRIGHTLIGHT cohort using the following identifiers: NHS 
Number, sex and postcode. The method for calculating the TYA CSS is adapted from an 
approach first proposed by Birch in 20131. 
 
Hospital activity within HES is recorded in three ways (Figure 1): 
1. Finished consultant episodes (FCEs) 
2. Spells (sequential hospital encounters with different consultants)  
3. Continuous inpatient spells (CIPS: hospital admissions for the same patient receiving 
care from different consultants and different providers/trust within two days after 
discharge)  
 
FCE is the standard measurement unit for hospital activity and considered to provide more 
accurate estimates of consultant workload and hospital resources2. FCE was used for the 
basis of analysis and derivation of the TYA CSS to ensure we used all available data on 
consultant care at the deepest level of granularity available. 
 
Figure 1: Different classifications of hospital admission for an example patient based on HES 
 
 
Abbreviation: FCEs -finished consultant episodes, CIPs -continuous inpatient spells, A-admission, D- discharge. 
Source: Analysing Patient-Level Data Using Hospital Episode Statistics (HES), University of York.  
                                               
1 Birch RJ. Teenage and young adult cancer in England – the patient journey and experience. The 
University of Leeds, PhD Thesis 2013 
2 Hargreaves DS, Viner RM. Adolescent inpatient activity 1999–2010: analysis of English Hospital 
Episode Statistics data. Archives of disease in childhood 2014; 99: 830-833 
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The development of the TYA CSS is summarised in Figure 2. 
 
Figure 2: Summary of the process for calculating the TYA CSS 
 
 
 
Data cleaning 
HES data were cleaned to remove duplicates and to clarify some of the diagnostic coding. 
Reference was made to the HES admitted patient care data dictionary3 to guide the data 
cleaning process in order to ensure accuracy and consistency in the recording and analysis 
of the HES records. 
 
Duplicates were removed to ensure there were not several copies of the same admission 
being recorded for the same patient. These were identified by ascertaining whether more 
                                               
3 HSCIC. HES data dictionary. HEALTH AND SOCIAL CARE INFORMATION CENTRE 2016, 20 
January 2016; Available from: http://www.hscic.gov.uk/hesdatadictionary 
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than one admission began on the same date for a single patient and then cross checking 
this against admission reasons, procedure codes and treating physician code. Examples of 
fields which would be indicative of duplicate admission records include multiple HES_IDs, 
episode start date, episode end date, admission date and discharge date.  
 
Location of specialist care centres 
The aim of the study is to evaluate the value of specialist cancer services. ‘Specialist’ was 
originally defined in the Improving Outcomes Guidance (IOG)4 as 13 principal treatment 
centres (PTCs) across England. To account for the age range of the BRIGHTLIGHT cohort 
starting at 13 years, PTCs also included children's PTCs where the age of admission for the 
TYA PTC did not include younger adolescents (Table 1). The hospital codes for the look up 
tables were taken from NHS Digital5. 
 
Calculation of the scale 
The level of specialist care received was calculated from the time of diagnosis (taken from 
the date recorded in the National Cancer Registration and Analysis Service dataset) 
1. Six months after diagnosis:  Spells in TYA PTC from diagnosis at 6 months/Total 
spells from diagnosis at 6 months 
2. 12 months after diagnosis: Spells in TYA PTC from diagnosis at 12 months/Total 
spells from diagnosis at 12 months 
 
For every individual, HES data were used to calculate the number of inpatient and day case 
bed days spent in a specialist centre (A), as well as the number of total bed days across all 
secondary care services (B) within the first 6 and 12 months after diagnosis. The proportion 
of time spent in a specialist centre was then derived as (A)/(B). 
 
Defining the levels of care 
Inpatient HES data were successfully linked to 1,074 out of 1,114 young people recruited to 
BRIGHTLIGHT. The distribution of the proportion of care by 6 months and 12 months after 
diagnosis suggested there were three natural groups occurring within the data (Figure 3). 
 
Figure 3: Distribution of the proportion of care receive in a TYA PTC 
 
       
                                               
4 National Institute for Health and Care Excellence. Guidance on cancer services: improving 
outcomes in children and young people with cancer. NICE, London 
2005https://www.nice.org.uk/guidance/csg7/resources/improving-outcomes-in-children-and-young-
people-with-cancer-update-773378893 [Accessed 30/08/18] 
5 https://digital.nhs.uk/services/organisation-data-service 
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Table 1:  List of principal treatment centres in England (2012-2014) for young people 
aged 13-24 years 
 
Principal Treatment Centre Hospital 
Cambridge University Hospitals NHS Foundation Trust Addenbrookes Hospital (aged 14-24) 
The Christie NHS Trust Christie Hospital (aged 16-24) 
Manchester University Hospitals NHS Foundation Trust Royal Manchester Children's Hospital  
(aged 13-15) 
Clatterbridge Centre for Oncology NHS Foundation 
Trust 
Clatterbridge Centre (aged 16-24) 
Alder Hey Children's NHS Foundation Trust Alder Hey Children's Hospital (aged 13-19) 
Royal Liverpool and Broadgreen University Hospital 
NHS Foundation Trust 
Royal Liverpool Hospital 
Royal Liverpool and Broadgreen University Hospital 
NHS Foundation Trust 
Broadgreen Hospital 
Leeds Teaching Hospitals NHS Trust Leeds General Infirmary (aged 13-16) 
Leeds Teaching Hospitals NHS Trust St James's University Hospital (aged 17-24) 
Nottingham University Hospitals NHS Trust City Campus (aged 18-24) 
Nottingham University Hospitals NHS Trust Queens Medical centre (aged 13-18) 
Sheffield Teaching Hospitals NHS Foundation Trust Weston Park Hospital (aged 16-24) 
Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital (aged 16-24) 
Sheffield Teaching Hospitals NHS Foundation Trust Sheffield Children's Hospital (aged 13-16) 
Southampton University Hospitals NHS Trust Southampton General Hospital (aged 16-24) 
Southampton University Hospitals NHS Trust Southampton Children's Hospital (aged 13-15) 
The Newcastle-upon-Tyne Hospitals NHS Foundation 
Trust 
Northern Centre for Cancer Care (aged 19-24) 
The Newcastle-upon-Tyne Hospitals NHS Foundation 
Trust 
Royal Victoria Infirmary (aged 13-18) 
The Royal Marsden NHS Foundation Trust The Royal Marsden Sutton (aged 13-24) 
The Royal Marsden NHS Foundation Trust The Royal Marsden Fulham (aged 17-24) 
University College London Hospitals NHS Foundation 
Trust 
University College Hospital (aged 13-24) 
University College London Hospitals NHS Foundation 
Trust 
Cancer Centre (aged 13-24) 
University Hospital Birmingham NHS Foundation Trust Queen Elizabeth Hospital (aged 16-24) 
Birmingham Children's Hospital NHS Trust Birmingham Children's Hospital (aged 13-18) 
University Hospital Bristol NHS Foundation Trust Bristol Haematology & Oncology Centre  
(aged 17-24) 
University Hospital Bristol NHS Foundation Trust Royal Hospital for Children (aged 11-16) 
University Hospital Bristol NHS Foundation Trust Bristol Royal Infirmary 
University Hospital Bristol NHS Foundation Trust St Michael's Hospital 
University Hospitals of Leicester NHS Trust Leicester Royal Infirmary (aged 13-24) 
Oxford University Hospital NHS Trust Churchill Hospital (aged 18-24) 
Oxford University Hospital NHS Trust John Radcliffe Children's Hospital  
(aged 13-18) 
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Supplementary File 2: Development of the BRIGHTLIGHT Severity of Illness Index 
(BRIGHTLIGHT SIX) 
 
Rationale for developing a bespoke severity index 
 
Within the BRIGHTLIGHT cohort, place of care was not randomly assigned but instead 
determined by local pathways of care, key influences including the type of cancer, age, 
proximity to principal treatment centres. As a consequence, differences exist between those 
who have all/some of their treatment in the teenage and young adult (TYA) Principal Treatment 
Centre (PTC) and those who have had no care in a TYA PTC. This fundamental difference 
between the populations of patients who receive no, some or all TYA PTC care was thought 
likely to be a major confounder in the interpretation of any observed differences in patient 
experience and outcome between these groups.  The differences may not be reflected 
accurately if cases were grouped solely by, say, tumour type or disease stage due to the 
considerable variation between tumour types and between similar tumours of different stages 
in the intensity of treatment received and the likelihood of survival. To interpret the significance 
of any observed differences in our primary or secondary outcome measures across the 
populations with no, some or all TYA PTC care, we needed a measure that would allow 
comparison across patients with different tumours, but capable of discriminating between 
patient populations. Our primary outcome was quality of life (QOL) and a powerful determinant 
of QOL is ‘the burden of cancer’ patients had at diagnosis1. We wished to consistently and 
systematically describe the burden of cancer to assist analysis. The severity of illness index 
therefore needed to reflect prognosis, disease morbidity (symptoms, physical impact) and 
treatment morbidity (determined by treatment duration, intensity and anticipated late morbidity 
burden).  
 
The BRIGHTLIGHT Severity of illness index (SIX) 
 
Constructing the index 
All cancer types were compared by symptom burden, treatment burden and prognosis using 
germ cell tumours as a reference:  Stage 1 – very likely to survive, treatment either surgery 
alone or surgery plus a limited burden of chemotherapy, few if any anticipated late effects of 
treatment; Stage 2-3 – ~90% survival, many have intensive or multimodality treatment or 
larger operations, some late toxicity burden; Stage 4 – 50% survival and intensive treatment. 
Stage 4 we classed as ‘most severe’ and used this as a reference point to compare odds of 
survival and treatment burden for other cancers. 
 
Germ cell tumours were chosen as a reference because they are relatively common in the 
TYA age group, have a range of prognoses from excellent to poor, and treatments have a 
range of morbidity from surgery alone through to very intensive chemotherapy with both acute 
and long-term sequelae.  
 
                                                 
1 Husson O, Zebrack BJ, Block R, Embry L, Aguilar C, Hayes-Lattin B, Cole S. Health-Related Quality 
of Life in Adolescent and Young Adult Patients With Cancer: A Longitudinal Study. J Clin Oncol 
2017;35:652-659 
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Three clinicians and two BRIGHTLIGHT researchers reviewed all cancer types to consider 
allocation to one of three severity levels.  Survival estimates were based on examination of 
current or recently completed trial protocols where available and using a recently published 
comprehensive TYA-specific reference textbook 2 . We evaluated treatment burden using 
duration and expected toxicity from multiple sources, including clinical experience, trial 
protocols, a current TYA oncology text book and international guidelines (such as the National 
Comprehensive Cancer Network). In addition, other potentially comparable clinical severity 
scales were sought from the literature to determine comparability or utility in this context.  
 
Content validity of the index 
Once a preliminary scale had been constructed, its content was tested by expert review.  At 
least two additional clinicians with specialist clinical expertise were approached to review each 
tumour type. The reviewers were sent a short document outlining the purpose of the scale and 
its development to that point as well as the scale itself.  They were interviewed either face-to-
face or by telephone by a senior clinician and BRIGHTLIGHT researcher (JSW) and asked to 
respond to two questions: 
1. Within the row(s) of the cancer types in which you have particular expertise (e.g. 
central nervous system tumours), do you agree with the allocation of grades of 
severity? 
2. Looking at other tumour types, by comparison with other rows, do you agree with the 
allocation of grades of severity? 
Interviews were recorded and field notes taken.  The scale was adjusted in response to expert 
comments to produce a final version (main paper, Table 2). 
 
Applying the BRIGHTLIGHT SIX 
 
BRIGHTLIGHT researchers (RMT, LAF, DS) independently allocated a severity level to each 
patient, conducting these assessments blind to responses to the survey, including QOL 
results. Comparisons between the three scores were made and, where there were differences, 
adjudication through a fourth researcher (JW) determined whether this was an error or due to 
ambiguity in the Index.  
 
Other measures of severity 
We found only one other example in which investigators had categorised TYA by cancer 
severity. Husson et al1 used expected 5-year survival to divide patients into three groups, 
those with expected survival of greater than 80%, 50-80% and less than 50%.3  Using the 
same source data4, we also allocated each patient from the BRIGHTLIGHT cohort a second 
severity level based on 5-year survival. 
 
We compared this method (Five year survival index, FYX) with BRIGHTLIGHT SIX. As 
anticipated, those judged to have the most severe cancer by BRIGHTLIGHT SIX are 
                                                 
2 Bleyer, Barr, Ries, Whelan, Ferrari eds. Cancer in Adolescents and Young Adults. Springer 
International Publishing, Switzerland 2017 
3 Husson O, Zebrack BJ, Block R, Embry L, Aguilar C, Hayes-Lattin B, Cole S. Health-Related Quality 
of Life in Adolescent and Young Adult Patients With Cancer: A Longitudinal Study. J Clin Oncol 
2017;35:652-659 
4 Bleyer, A. (2011). "Latest Estimates of Survival Rates of the 24 Most Common Cancers in 
Adolescent and Young Adult Americans." J Adolesc Young Adult Oncol 1(1): 37-42. 
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distributed across the three survival categories though weighted towards the two lower 
survival groups.  Similarly, most but not all of those with the least severe cancer by 
BRIGHTLIGHT SIX had the best expected survival. Those with intermediate severity cancer 
are spread across the three FYX groups (Table 1).  
 
Table 1: Comparison between the Five year survival Index (FYX) and BRIGHTLIGHT 
Severity of Illness Index (SIX)  
 SIX level 
FYX Least Intermediate Most 
<50% 1 100 71 
50-80% 56 98 171 
>80% 546 56 7 
 
We then analysed survival of the BRIGHTLIGHT cohort using the two indices. Figure 1 
demonstrated a clear discrimination in survival by BRIGHTLIGHT SIX, consistent with 
anticipated survival being an important but not sole component of the index. The survival of 
the BRIGHTLIGHT cohort was then examined by allocated FYX category (Figure 2). FYX 
failed to distinguish three groups with distinct survival as that of those allocated to the two 
lower categories was superimposed.  
 
Figure 1: Survival by BRIGHTLIGHT Severity of Illness Index  
 
 
 
 
(log rank test P-value<0.001) 
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Figure 2: Survival of BRIGHTLIGHT cohort against allocated FYX group  
 
 
 
(log rank test P-value <0.001) 
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STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)
Section/Topic Item # Recommendation Reported on page #
(a) Indicate the study’s design with a commonly used term in the title or the abstract 1Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 3
Objectives 3 State specific objectives, including any pre-specified hypotheses 5
Methods
Study design 4 Present key elements of study design early in the paper 5
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection
5
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants
5-6Participants 6
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed
Case-control study—For matched studies, give matching criteria and the number of controls per case
Not applicable
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable
6-9
Data sources/ measurement 8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group
6-9
Bias 9 Describe any efforts to address potential sources of bias 7
Study size 10 Explain how the study size was arrived at Not applicable
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why
10
(a) Describe all statistical methods, including those used to control for confounding 10
(b) Describe any methods used to examine subgroups and interactions Not applicable
(c) Explain how missing data were addressed Not applicable
Statistical methods 12
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed
Not applicable – only 
reporting baseline 
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Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy characteristics
(e) Describe any sensitivity analyses Not applicable
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed
Figure 2
(b) Give reasons for non-participation at each stage Figure 2
(c) Consider use of a flow diagram Figure 2
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders
12
(b) Indicate number of participants with missing data for each variable of interest Tables 3-5
(c) Cohort study—Summarise follow-up time (eg, average and total amount) Not applicable, 
presenting wave 1 
data only
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Not applicable – wave 
1 descriptive data 
only
Case-control study—Report numbers in each exposure category, or summary measures of exposure Not applicable
Cross-sectional study—Report numbers of outcome events or summary measures Not applicable
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included
Descriptive data only 
presented
(b) Report category boundaries when continuous variables were categorized Not applicable
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion
Key results 18 Summarise key results with reference to study objectives 18
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias
18
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence
19
Generalisability 21 Discuss the generalisability (external validity) of the study results 18-19
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based
25
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*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
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